IG
TEVA icon

ING Group’s Teva Pharmaceuticals TEVA Stock Holding History

ING Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,600
Closed -$16.3K – 654
2023
Q3 		$16.3K Hold
1,600
– – ﹤0.01% 582
2023
Q2 		$12K Hold
1,600
– – ﹤0.01% 521
2023
Q1 		$14.2K Buy
+1,600
New +$15.8K ﹤0.01% 615
2019
Q3 		– Sell
-46,470
Closed -$429K – 723
2019
Q2 		$429K Buy
46,470
+23,500
+102% +$283K 0.01% 561
2019
Q1 		$360K Buy
22,970
+4,000
+21% +$70.5K 0.01% 551
2018
Q4 		$293K Sell
18,970
-4,500
-19% -$92.3K 0.01% 591
2018
Q3 		$506K Buy
23,470
+6,890
+42% +$160K 0.01% 507
2018
Q2 		$403K Buy
16,580
+6,000
+57% +$122K 0.01% 525
2018
Q1 		$181K Sell
10,580
-11,300
-52% -$221K ﹤0.01% 693
2017
Q4 		$415K Sell
21,880
-3,150
-13% -$47.4K 0.01% 552
2017
Q3 		$441K Sell
25,030
-25,990
-51% -$585K 0.01% 537
2017
Q2 		$1.7M Sell
51,020
-2,000
-4% -$61.9K 0.03% 240
2017
Q1 		$1.7M Buy
+53,020
New +$1.81M 0.03% 273
2016
Q4 		– Sell
-6,030
Closed -$279K – 604
2016
Q3 		$279K Buy
6,030
+480
+9% +$25K ﹤0.01% 511
2016
Q2 		$279K Hold
5,550
– – ﹤0.01% 447
2016
Q1 		$297K Hold
5,550
– – ﹤0.01% 453
2015
Q4 		$364K Hold
5,550
– – ﹤0.01% 591
2015
Q3 		$313K Hold
5,550
– – ﹤0.01% 530
2015
Q2 		$328K Sell
5,550
-10,000
-64% -$617K ﹤0.01% 588
2015
Q1 		$969K Hold
15,550
– – ﹤0.01% 598
2014
Q4 		$894K Sell
15,550
-12,000
-44% -$669K ﹤0.01% 592
2014
Q3 		$1.48M Hold
27,550
– – 0.01% 493
2014
Q2 		$1.44M Sell
27,550
-54,214
-66% -$2.77M 0.01% 494
2014
Q1 		$4.32M Buy
81,764
+65,532
+404% +$3.03M 0.02% 390
2013
Q4 		$651K Sell
16,232
-10,581
-39% -$417K ﹤0.01% 590
2013
Q3 		$1.01M Buy
26,813
+9,788
+57% +$382K 0.01% 565
2013
Q2 		$667K Buy
+17,025
New +$663K ﹤0.01% 582

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

ING Group's TEVA Position: Q4 2023 in Review

ING Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 1,600 shares — an estimated $16.3K sold.

ING Group first reported a position in TEVA in Q2 2013 and held it in 27 quarters. The position peaked at $4.32M in Q1 2014. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • ING Group reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • ING Group sold 1,600 Teva Pharmaceuticals shares in Q4 2023, an estimated $16.3K.
  • ING Group first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • ING Group's Teva Pharmaceuticals position peaked at $4.32M in Q1 2014.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on ING Group's 13F filing for Q4 2023, filed 8 Feb 2024.